All the Therapeutic System Drugs
Anti-Androgen. Cyproterone 2 mg, Ethinylestradiol 35 mcg. COATED TABS: 21. 1 tab. dly. for 21 days,
starting 1st day of menstrual cycle.
Signs of androgenization in women:
Pronounced forms acne, androgenat.
alopecia, mild forms hirsutism.
Concom. use with another hormone. contraceptive.
VT present or in history (DVT, PE)
Arter. thrombos. present or in hist. (e.g. MI) or prodromal conditions (e.g.angina p.and TIA).
Presence or hist. of cerebrovasc.accident
The presence of a severe or multiple risk factor(s) for venous/ arterial thrombos. such as: diabetes mell. with vasc. sympt., severe hypertens., severe dyslipoproteinaemia
Heredit. or acquired predisposit. for venous/ arterial thrombosis, such as activated protein C.
(APC) resistance, antithrombin-III-defic., protein C defic., protein S defic., hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant).
History of migraine with focal neurology. sympt.
Presence or hist.of severe hep. dis.e.g. active viral hepatitis and severe cirrhosis, as long as liver funct. values have not returned to normal.
Presence or history of liver tumours (benign or malignant).
Current or history of breast canc.
Meningioma or history of meningioma.
Known or suspected preg.
5-α Reductase Inhibitor. Finasteride 1 mg. TABS: 1 mg x 30, 100.
1 mg tablet x 1 dly. May be taken with/
Effic., durat. of tmt. should contin. be
assessed by the treat. physic. Gener., 3
or more mths. of once dly. tmt. are
required before evidence of benefit is
observed. Contin. use is recom. to sustain benefit, which should be
Tmt. of men with male pattern hair loss
(androgenetic alopecia) to incr. hair
growth and prevent further hair loss.
C/I: Hypersens. to product, not for use in
women and child., not to be used in
comb. with any other med. contain.
Finasteride, Dutasteride, preg.